Literature DB >> 2861663

Hypercortisolism, diarrhea with steatorrhea, and massive proteinuria due to pheochromocytoma.

J W Interlandi, R F Hundley, A G Kasselberg, D N Orth, W D Salmon, J N Sullivan.   

Abstract

Amelioration or cure of hypertension, hypercortisolism, diarrhea with steatorrhea, and massive proteinuria resulted from excision of a pheochromocytoma that contained immunoreactive ACTH, VIP, and somatostatin. Ectopic ACTH production by the tumor was clearly the cause of the hypercortisolism, and the possible involvement of VIP and somatostatin in the diarrhea and steatorrhea was considered. The response to tumor removal suggested that the mesangioproliferative glomerulonephritis shown on renal biopsy was also a paraneoplastic phenomenon.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2861663     DOI: 10.1097/00007611-198507000-00029

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  3 in total

1.  Ectopic hormone-secreting pheochromocytoma: a francophone observational study.

Authors:  James Kirkby-Bott; Laurent Brunaud; Muriel Mathonet; Etienne Hamoir; Jean-Louis Kraimps; Christophe Trésallet; Laurence Amar; Alexandre Rault; Jean-Francois Henry; Bruno Carnaille
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

2.  Cyclic Cushing's syndrome due to ectopic ACTH secretion by an adrenal pheochromocytoma.

Authors:  M Terzolo; A Alì; A Pia; E Bollito; G Reimondo; P Paccotti; R Scardapane; A Angeli
Journal:  J Endocrinol Invest       Date:  1994-12       Impact factor: 4.256

Review 3.  Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Authors:  M Schmidt-Hieber; J Bierwirth; D Buchheidt; O A Cornely; M Hentrich; G Maschmeyer; E Schalk; J J Vehreschild; Maria J G T Vehreschild
Journal:  Ann Hematol       Date:  2017-11-24       Impact factor: 3.673

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.